Finance

Beta
Lists
LIMN:NASDAQ
Liminatus Pharma Inc
$0.14
-8.33%
(-0.013) 1D
Jun 5, 3:02:18 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LIMN...
Open
$0.15
High
$0.15
Low
$0.14
Mkt. cap
6.27M
Avg. vol.
14.84M
Volume
2.53M
52-wk high
$33.66
52-wk low
$0.13
EPS
-$0.58
Beta
0.73
Shares outstanding
44.88M
No. of employees
1
Open
$0.15
High
$0.15
Low
$0.14
Mkt. cap
6.27M
Avg. vol.
14.84M
Volume
2.53M
52-wk high
$33.66
52-wk low
$0.13
EPS
-$0.58
Beta
0.73
Shares outstanding
44.88M
No. of employees
1
News stories
From sources across the web
About Liminatus Pharma Inc
CEO-
Employees1
Founded-
HeadquartersLa Palma, California, United States
SectorBiotechnology
Websiteliminatuspharma.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
-
-
-
400.00K
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.12M
701.17K
884.21K
700.90K
Operating expense
1.12M
701.17K
884.21K
1.10M
Total operating expenses
1.12M
701.17K
884.21K
1.10M
Operating income
-1.12M
-701.17K
-884.21K
-1.10M
Other non operating income
-116.89K
-1.66M
-101.66K
-4.18K
EBT including unusual items
113.29K
-1.82M
-8.17M
-1.12M
EBT excluding unusual items
-1.27M
-2.38M
-1.00M
-1.12M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
113.29K
-1.82M
-8.17M
-1.12M
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
24.38K
-
-
-
Interest expense
-62.29K
-19.05K
-19.05K
-18.64K
Net interest expenses
-37.90K
-19.05K
-19.05K
-18.64K
Depreciation and amortization charges
-
-
-
-
EBITDA
-1.12M
-700.63K
-883.67K
-1.10M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer